BAJAJ BROKING

Notification close image
No new Notification messages
card image
Oswal Pumps IPO is Open!
Apply for the Oswal Pumps IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

24715

544222

AKUMS

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

AKUMS DRUGS AND PHARMA L performance

Today’s low

Today’s high

₹ 555.00 ₹ 578.50
₹ 572.30

52 week low

52 week high

₹ 405.00 ₹ 1175.90
₹ 572.30

Open Price

₹ 556.60

Prev. Close

₹ 569.35

Volume (Shares)

111344.00

Total traded value

₹ 637.22

Upper Circuit

₹ 626.25

Lower Circuit

₹ 512.45

info

AKUMS DRUGS AND PHARMA L Share Price Update

As of the latest trading session, AKUMS DRUGS AND PHARMA L share price is currently at ₹ 572.3, which is up by ₹ 2.95 from its previous closing. Today, the stock has fluctuated between ₹ 555.00 and ₹ 578.50. Over the past year, AKUMS DRUGS AND PHARMA L has achieved a return of -28.12 %. In the last month alone, the return has been 11.52 %. Read More...

AKUMS DRUGS AND PHARMA L fundamentals


  • Market cap (Cr)

    9,007.70

  • P/E Ratio (TTM)

    55.84

  • Beta

    1.29

  • Book Value / share

    146.51

  • Return on equity

    -69.32%

  • EPS (TTM)

    10.23

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    27.59

info icon alternate text
  • Market cap (Cr)

    8,990.30

  • P/E Ratio (TTM)

    55.84

  • Beta

    1.25

  • Book Value / share

    146.51

  • Return on equity

    -69.32%

  • EPS (TTM)

    10.23

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    27.59

info icon alternate text

AKUMS DRUGS AND PHARMA L Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars MAR 2025 (Values in Cr)
Revenue 328.75
Operating Expense 323.75
Net Profit 27.59
Net Profit Margin (%) 8.39
Earnings Per Share (EPS) 1.80
EBITDA 49.78
Effective Tax Rate (%) 25.55
Particulars DEC 2024 (Values in Cr)
Revenue 337.41
Operating Expense 316.35
Net Profit 41.17
Net Profit Margin (%) 12.20
Earnings Per Share (EPS) 2.69
EBITDA 67.86
Effective Tax Rate (%) 24.99
Particulars SEP 2024 (Values in Cr)
Revenue 328.35
Operating Expense 298.85
Net Profit 50.37
Net Profit Margin (%) 15.34
Earnings Per Share (EPS) 3.38
EBITDA 75.19
Effective Tax Rate (%) 18.25
Particulars JUN 2024 (Values in Cr)
Revenue 317.28
Operating Expense 289.18
Net Profit 41.88
Net Profit Margin (%) 13.19
Earnings Per Share (EPS) 2.93
EBITDA 69.86
Effective Tax Rate (%) 22.84
Particulars MAR 2024 (Values in Cr)
Revenue 298.35
Operating Expense 372.77
Net Profit -57.87
Net Profit Margin (%) -19.39
Earnings Per Share (EPS) -4.04
EBITDA -35.15
Effective Tax Rate (%) -18.00
Particulars MAR 2025 (Values in Cr)
Revenue 1311.78
Operating Expense 1228.13
Net Profit 161.00
Net Profit Margin (%) 12.27
Earnings Per Share (EPS) 10.76
EBITDA 262.70
Effective Tax Rate (%) 22.53
Particulars MAR 2024 (Values in Cr)
Revenue 1444.12
Operating Expense 1621.78
Net Profit -165.45
Net Profit Margin (%) -11.45
Earnings Per Share (EPS) -11.56
EBITDA -51.93
Effective Tax Rate (%) -60.74
Particulars MAR 2023 (Values in Cr)
Revenue 1286.83
Operating Expense 1088.13
Net Profit 125.43
Net Profit Margin (%) 9.74
Earnings Per Share (EPS) 8.77
EBITDA 193.50
Effective Tax Rate (%) 16.55
Particulars MAR 2022 (Values in Cr)
Revenue 1162.06
Operating Expense 1555.51
Net Profit -381.78
Net Profit Margin (%) -32.85
Earnings Per Share (EPS) -53.33
EBITDA -303.57
Effective Tax Rate (%) -13.97
Particulars MAR 2021 (Values in Cr)
Revenue 837.44
Operating Expense 837.66
Net Profit -145.43
Net Profit Margin (%) -17.36
Earnings Per Share (EPS) -20.33
EBITDA -168.28
Effective Tax Rate (%) 25.49
Particulars MAR 2024 (Values in Cr)
Book Value / Share 49.59
ROE % -3.57
ROCE % 1.24
Total Debt to Total Equity 0.83
EBITDA Margin 3.76
Particulars MAR 2023 (Values in Cr)
Book Value / Share 50.13
ROE % 19.46
ROCE % 11.73
Total Debt to Total Equity 0.76
EBITDA Margin 10.32
Particulars MAR 2022 (Values in Cr)
Book Value / Share 86.95
ROE % -33.30
ROCE % -9.43
Total Debt to Total Equity 0.33
EBITDA Margin -2.23
Particulars MAR 2021 (Values in Cr)
Book Value / Share 6801.28
ROE % 15.36
ROCE % 11.63
Total Debt to Total Equity 0.17
EBITDA Margin 9.14
Particulars MAR 2020 (Values in Cr)
Book Value / Share 5554.41
ROE % 6.04
ROCE % 9.29
Total Debt to Total Equity 0.24
EBITDA Margin 8.30
Particulars MAR 2024 (Values in Cr)
Book Value / Share 10.06
ROE % -69.32
ROCE % -3.93
Total Debt to Total Equity 0.82
EBITDA Margin -2.25
Particulars MAR 2023 (Values in Cr)
Book Value / Share 21.77
ROE % 92.77
ROCE % 21.17
Total Debt to Total Equity 0.57
EBITDA Margin 26.27
Particulars MAR 2022 (Values in Cr)
Book Value / Share 25.94
ROE % -101.46
ROCE % -25.83
Total Debt to Total Equity 0.22
EBITDA Margin -26.12
Particulars MAR 2021 (Values in Cr)
Book Value / Share 4358.55
ROE % 17.25
ROCE % 4.52
Total Debt to Total Equity 0.05
EBITDA Margin 9.70
Particulars MAR 2020 (Values in Cr)
Book Value / Share 5476.91
ROE % 6.55
ROCE % 7.36
Total Debt to Total Equity 0.06
EBITDA Margin 14.31
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 277.05
Total Assets 3516.36
Total Liabilities 3516.36
Total Equity 720.48
Share Outstanding 143064350
Price to Book Ratio 0.00
Return on Assets (%) -0.11
Return on Capital (%) -0.33
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 149.98
Total Assets 3266.52
Total Liabilities 3266.52
Total Equity 723.37
Share Outstanding 143064350
Price to Book Ratio 0.00
Return on Assets (%) 2.90
Return on Capital (%) 7.53
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 102.84
Total Assets 3069.04
Total Liabilities 3069.04
Total Equity 625.17
Share Outstanding 71532175
Price to Book Ratio 0.00
Return on Assets (%) -8.22
Return on Capital (%) -25.69
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 67.86
Total Assets 2192.01
Total Liabilities 2192.01
Total Equity 887.13
Share Outstanding 1300585
Price to Book Ratio 0.00
Return on Assets (%) 5.63
Return on Capital (%) 12.67
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 147.36
Total Assets 2078.27
Total Liabilities 2078.27
Total Equity 720.88
Share Outstanding 1300585
Price to Book Ratio 0.00
Return on Assets (%) 2.10
Return on Capital (%) 5.07
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 73.31
Total Assets 2095.42
Total Liabilities 2095.42
Total Equity 143.87
Share Outstanding 143064350
Price to Book Ratio 0.00
Return on Assets (%) -7.89
Return on Capital (%) -44.7
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 8.84
Total Assets 1894.20
Total Liabilities 1894.20
Total Equity 311.50
Share Outstanding 143064350
Price to Book Ratio 0.00
Return on Assets (%) 6.62
Return on Capital (%) 27.44
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 25.73
Total Assets 1813.94
Total Liabilities 1813.94
Total Equity 185.53
Share Outstanding 71532175
Price to Book Ratio 0.00
Return on Assets (%) -21.04
Return on Capital (%) -124.1
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.99
Total Assets 1298.35
Total Liabilities 1298.35
Total Equity 567.04
Share Outstanding 1300585
Price to Book Ratio 0.00
Return on Assets (%) -11.20
Return on Capital (%) -24.66
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 72.47
Total Assets 1426.26
Total Liabilities 1426.26
Total Equity 712.31
Share Outstanding 1300585
Price to Book Ratio 0.00
Return on Assets (%) 3.56
Return on Capital (%) 6.8
Particulars MAR 2024 (Values in Cr)
Net Income -45.27
Cash from Operations 560.67
Cash from Investing -330.41
Cash from Financing -108.02
Net change in Cash 59.82
Free Cash Flow 872.08
Particulars MAR 2023 (Values in Cr)
Net Income 150.29
Cash from Operations 273.69
Cash from Investing -304.70
Cash from Financing 124.54
Net change in Cash -3.53
Free Cash Flow 602.48
Particulars MAR 2022 (Values in Cr)
Net Income -193.19
Cash from Operations 86.67
Cash from Investing -234.82
Cash from Financing 236.04
Net change in Cash 33.07
Free Cash Flow 344.25
Particulars MAR 2021 (Values in Cr)
Net Income 172.26
Cash from Operations 180.43
Cash from Investing -109.38
Cash from Financing -95.22
Net change in Cash -69.72
Free Cash Flow 263.24
Particulars MAR 2020 (Values in Cr)
Net Income 113.82
Cash from Operations 76.85
Cash from Investing -189.86
Cash from Financing 233.01
Net change in Cash 71.28
Free Cash Flow 138.91
Particulars MAR 2024 (Values in Cr)
Net Income -102.93
Cash from Operations 247.88
Cash from Investing -165.44
Cash from Financing -20.74
Net change in Cash 61.72
Free Cash Flow 319.74
Particulars MAR 2023 (Values in Cr)
Net Income 150.31
Cash from Operations 35.57
Cash from Investing -202.16
Cash from Financing 89.90
Net change in Cash -18.25
Free Cash Flow 151.83
Particulars MAR 2022 (Values in Cr)
Net Income -334.97
Cash from Operations 235.50
Cash from Investing -297.95
Cash from Financing 94.98
Net change in Cash 25.34
Free Cash Flow 265.79
Particulars MAR 2021 (Values in Cr)
Net Income -195.19
Cash from Operations -242.91
Cash from Investing -99.96
Cash from Financing 2.59
Net change in Cash -41.78
Free Cash Flow -209.83
Particulars MAR 2020 (Values in Cr)
Net Income 75.85
Cash from Operations 22.37
Cash from Investing -241.71
Cash from Financing 301.53
Net change in Cash 38.06
Free Cash Flow 53.83
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.36 27.76 1.99 278.64 34.11 / 77.70
BLISS GVS PHARMA LTD 149.35 18.67 1.49 1573.70 101.00 / 184.95
CIPLA LTD 1505.40 23.06 3.89 121589.70 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 338.10 12.94 2.74 995.06 163.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.36 36.36 5.74 278.64 34.11 / 77.70
AMRUTAJAN HEALTH LTD 697.60 39.68 6.17 2016.81 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 10524.65 150.31 34.15 26311.63 6160.25 / 10653.05
BLISS GVS PHARMA LTD 149.35 22.80 1.48 1573.70 101.00 / 184.95

AKUMS DRUGS AND PHARMA L Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
572.30 0.51 redarrow
red-green-graph indicator
2 Bearish
14 Bullish
  • 5 Days 570.20
  • 26 Days 556.10
  • 10 Days 568.00
  • 50 Days 543.30
  • 12 Days 567.00
  • 100 Days 561.20
  • 20 Days 561.10
  • 200 Days 650.40
574.47 PIVOT

First Support

561.83

First Resistance

581.98

Second Support

554.32

Second Resistance

594.62

Third Support

541.68

Third Resistance

602.13

RSI

59.55

ADX

61.08

MACD

10.91

Williams % R

-70.45

Commodity Channel Index (CCI)

-2.35

Date

2025-06-13

Week

67366.00

Same Day

51290.00

Month

112459.00

1 Year

1.29

3 Year

1.30

Over 1 Month

11.52%

down

Over 1 Year

-28.12%

down

Over 3 Months

12.16%

down

Over 3 Years

0.00%

down

Over 6 Months

-2.88%

down

Over 5 Years

0.00%

down

AKUMS DRUGS AND PHARMA L shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
11.57%
Promoter Holdings
75.26%
FII
5.76%
DII
7.39%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Akums Master Trust (sanjeev Jain And Sandeep Jain) 6.42E7 (40.79%) Shareholding of Promoter and Promoter Group
Sandeep Jain 2.712769E7 (17.24%) Shareholding of Promoter and Promoter Group
Sanjeev Jain 2.711394E7 (17.23%) Shareholding of Promoter and Promoter Group
Ruby Qc Investment Holdings Pte Ltd 7278535.0 (4.62%) Public Shareholding
Franklin India Smaller Companies Fund 5202914.0 (3.31%) Public Shareholding
Smallcap World Fund, Inc 2667577.0 (1.69%) Public Shareholding
Lata Jain 13750.0 (0.01%) Shareholding of Promoter and Promoter Group
Manan Jain 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Kanishk Jain 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Umang Jain 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Arushi Jain 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Shivangi Jain 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Rajiv Mittal 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Rajesh Sharma 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Kusum Jain 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Kiran Jain 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Archana Jain 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Anuradha Pal 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Anita Jain 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Sudha Jain 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Neerja Gupta 0.0 (0.0%) Shareholding of Promoter and Promoter Group
May & Baker Pharmaceuticals Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Hygosap Pharma Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Amazing Research & Laboratories Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Welcure Pharmaceuticals Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Parke Davis Healthcare Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Dhanwantri Vedaresearch Llp 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Delcure Lifesciences Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Avha Lifesciences Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
American Remedies Lifesciences Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Akums Foundation 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Akum Impex Llp 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Akome Lifecare Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Sandeep Jain Trust (sandeep Jain) 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Ausl Trust (sanjeev Jain) 0.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

AKUMS DRUGS AND PHARMA L corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

AKUMS DRUGS AND PHARMA L Share Price

Akums Drugs and Pharmaceuticals Limited was incorporated vide Certificate of Incorporation dated April 19, 2004 and received a Certificate for Commencement of Business dated May 13, 2004 issued by the RoC.

Alkums Drugs & Pharmas are a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. They are into sale of branded pharmaceutical formulations and manufacturing of Active Pharmaceutical Ingredients. Some of the other services include formulation research and development, preparation and filing of regulatory dossiers into the Indian and global markets, and other testing services. Some of manufacturing units have been accredited by various global regulatory agencies such as the European Good Manufacturing Practice, the World Health Organization Good Manufacturing Practice and the United States National Sanitation Foundation. Their specialization extends to development and sale of APIs across diverse chemical processes and therapeutic areas such as anti-infective, respiratory and diabetes.

In 2004, the Company established first plant for oral dosage commissioned at 19, 20, 21, Sector 6A, Haridwar, Uttarakhand. In 2007, it established dedicated manufacturing site for oral liquid dosage and sterile products both at Haridwar, Uttarakhand. It incorporated Maxcure Nutravedics Limited to venture into nutraceuticals in 2009. In 2010, it dedicated a facility for hormones ; dedicated a facility for cosmetics and dermatology at Haridwar, Uttarakhand. In 2010, it incorporated Akumentis Healthcare Limited to venture into branded formulations.

In 2011, it innovated bi-layered sustained release tablets for the first time. In 2012, acquired subsidiary, Pure and Cure Healthcare Private Limited to expand capacity and capabilities. In 2013, it acquired Malik Lifesciences Private Limited manufacturing sites to expand capacity and capabilities. It established R&D Laboratory in Mumbai, Maharashtra to venture into regulated market in 2015.

In 2021, the Company acquired Parabolic Drugs to form Akums Lifesciences Limited and ventured into APIs. Further, it acquired Kotdwar Plant in Uttarakhand by Akums Healthcare Limited. In 2022, it acquired facility in Haridwar, Uttarakhand through the subsidiaries, Akums Healthcare Limited and in 2023, acquired Baddi facility in, Himachal Pradesh through Pure and Cure Healthcare Private Limited

Following a Scheme of Arrangement on October 17, 2023, Akums Lifesciences Limited got merged with its subsidiary, Pure and Cure Healthcare Private Limited (PCHL) with effect from April 1, 2022. As part of this acquisition, it acquired manufacturing units in Dera Bassi and Lalru in Punjab and Barwala in Haryana, and an R&D centre in Barwala, Haryana and commenced operations in the manufacture and sale of key starting materials, intermediates and APIs.

The Company launched an IPO by issuing 27,368,151 equity shares of Rs 2 each by raising funds aggregating to Rs 1857 Crore comprising a fresh issue of 10,037,716 equity shares aggregating to Rs 680 Crore and offer for sale of 17,330,435 equity shares aggregating to Rs 1177 Crore in August, 2024.

Parent organization Indian Private
NSE symbol AKUMS
Founded 2004
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Akums Drugs & Pharmaceuticals Ltd?

Answer Field

The share price of Akums Drugs & Pharmaceuticals Ltd for NSE is ₹ 572.30 and for BSE is ₹ 570.65.

What is the Market Cap of Akums Drugs & Pharmaceuticals Ltd?

Answer Field

The market cap of Akums Drugs & Pharmaceuticals Ltd for NSE is ₹ 8,187.57 Cr. and for BSE is ₹ 8,163.96 Cr. as of now.

What is the 52 Week High and Low of Akums Drugs & Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Akums Drugs & Pharmaceuticals Ltd for NSE is ₹ 1,175.90 and ₹ 405.00 and for BSE is ₹ 1,174.85 and ₹ 407.40.

How to Buy Akums Drugs & Pharmaceuticals Ltd share?

Answer Field

You can trade in Akums Drugs & Pharmaceuticals Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Akums Drugs & Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been -28.12%.

What is the Current Share Price of Akums Drugs & Pharmaceuticals Ltd?

Answer Field

Akums Drugs & Pharmaceuticals Ltd share price is for NSE ₹ 572.30 & for BSE ₹ 570.65 as on Jun 13 2025 03:30 PM.

What is the Market Cap of Akums Drugs & Pharmaceuticals Ltd Share?

Answer Field

The market cap of Akums Drugs & Pharmaceuticals Ltd for NSE ₹ 8,187.57 & for BSE ₹ 8,163.96 as on Jun 13 2025 03:30 PM.

What is the P/E Ratio of Akums Drugs & Pharmaceuticals Ltd Share?

Answer Field

As on Jun 13 2025 03:30 PM the price-to-earnings (PE) ratio for Akums Drugs & Pharmaceuticals Ltd share is 55.84.

What is the PB ratio of Akums Drugs & Pharmaceuticals Ltd Share?

Answer Field

As on Jun 13 2025 03:30 PM, the price-to-book (PB) ratio for Akums Drugs & Pharmaceuticals Ltd share is 146.51.

How to Buy Akums Drugs & Pharmaceuticals Ltd Share?

Answer Field

You can trade in Akums Drugs & Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Akums Drugs & Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Akums Drugs & Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Akums Drugs & Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|